Fresh From the Bench: Latest Federal Circuit Court Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Littelfuse, Inc. v. Mersen USA EP Corp., Appeal No. 2021-2013 (Fed. Cir. Apr. 4, 2022)
Our Case of the Week focuses on the issue of claim construction, and, more specifically, the doctrine of claim differentiation.
The patent at issue was directed to a “fuse end cap for providing an electrical connection between a fuse and an electrical conductor.” The patent described three embodiments of end caps: a “machined end cap,” a “stamped end cap,” and an “assembled end cap.” The first two may be made from a single piece of material that is either machined or otherwise formed into the end cap. The last is made from two separate pieces of material.
Read More.
By Nika Aldrich
ALSO THIS WEEK
Roche Diagnostics Corporation v. Meso Scale Diagnostics, LLC, Appeal Nos. 2021-1609, -1633 (Fed. Cir. April 8, 2022)
In an appeal from a district court decision, the Court addressed a licensing dispute in a lengthy opinion covering numerous legal and factual issues. Roche filed for declaratory judgement for non-infringement of patents, the rights to which Meso claimed to hold via an exclusive license. Meso counterclaimed for infringement. The jury found that Meso held an exclusive license to the asserted patent claims and that Roche directly infringed one claim, induced infringement of three claims, and did so willfully. The district court granted Roche judgement as a matter of law on willfulness, denied Meso’s motions to enhance damages, and granted Roche’s request for a finding of non-infringement on three additional patents, due to their being compulsory counterclaims that Meso failed to bring in its counterclaim. Given insufficient reason to overturn the district court’s finding that the patents-in-suit were within the scope of rights licensed exclusively to Meso, the Federal Circuit affirmed on direct infringement. On induced infringement, the Federal Circuit reversed the district court on both the intent and inducing acts prongs. The Federal Circuit agreed with Roche that, because the intent standard for induced infringement is similar to the intent standard for willfulness and enhanced damages, the same facts that led to JMOL on willfulness and denial of enhanced damages should have led to JMOL on induced infringement. The Federal Circuit also agreed that, although the induced infringing acts occurred during the six-year window prior to suit, because the acts that induced the infringing acts occurred before the six-year window, the induced acts prong was not met. Because the Federal Circuit reversed on induced infringement, it vacated for a new trial on damages. The Federal Circuit also vacated the non-infringement finding as to the three additional patents, agreeing with Meso that a counterclaim that is compulsory but not brought is barred in subsequent actions, but not in a present action. The Federal Circuit did not reach the question of whether Roche’s complaint was too generic to trigger the compulsory counterclaim rule, saving that determination for any district court called to hear a subsequent infringement action by Meso concerning the additional patents. In dissent, Judge Newman argued that Roche cannot infringe patents it owns, and, detailing the complicated history of the patents-in-suit, that Roche had owned the patents since 2007.
The opinion can be found here.
By Tyler Hall
Edited by: Scott D. Eads and Nika Aldrich, Schwabe Williamson & Wyatt
Contributor: Tyler Hall
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…